A carregar...

Factors associated with potentially inappropriate phosphodiesterase-5 inhibitor use for pulmonary hypertension in the US, 2006–2015

BACKGROUND: Use of phosphodiesterase-5 inhibitors for Groups 2 and 3 pulmonary hypertension is rising nationally, despite guidelines recommending against this low-value practice. Although receiving care across healthcare systems is encouraged to increase Veterans’ access to specialists critical for...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circ Cardiovasc Qual Outcomes
Main Authors: Gillmeyer, Kari R., Rinne, Seppo T., Glickman, Mark E., Lee, Kyung Min, Shao, Qing, Qian, Shirley X., Klings, Elizabeth S., Maron, Bradley A., Hanlon, Joseph T., Miller, Donald R., Wiener, Renda Soylemez
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7344878/
https://ncbi.nlm.nih.gov/pubmed/32393128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCOUTCOMES.119.005993
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!